Scynexis Will Use Contract Commercial Firm To Market Novel Antifungal

 
• By Joseph Haas

Scynexis obtained US FDA approval of ibrexafungerp, from the first novel class of antifungals in 20 years, and plans to use a contractor for US marketing of Brexafemme for vaginal yeast infections caused by Candida fungi.

Scynexis
With Brexafemme approval, Scynexis has its first commercial product • Source: Scynexis

More from New Products

More from Scrip